Our newest product delivers real-time route optimization and threat avoidance for tactical airlift, special mission, ...

ROCKVILLE, Md., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a clinical-stage company developing therapeutics designed to treat cancer and ...

VIRAGE2 exploratory study designed to refine dosing regimen to potentially improved outcomes in a future pivotal Phase 3 clinical trial -- ...

Theriva Biologics announced that its VIRAGE Phase 2b clinical trial of VCN-01, an oncolytic adenovirus treatment for metastatic pancreatic ductal adenocarcinoma, met its primary efficacy and safety ...

– Dosed the first patient in VIRAGE, a Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma – – Dosed the first patient in ...

Intriguing historical observations that some viral infections can promote cancer remission have led to investigations of the therapeutic potential of oncolytic viruses that replicate, infect and ...

"We are very pleased with the European Commission's grant of orphan medicinal product designation to VCN-01, emphasizing the urgent need for new treatment options for retinoblastoma,” said Steven A.

"We are very pleased with the European Commission's grant of orphan medicinal product designation to VCN-01, emphasizing the urgent need for new treatment options for retinoblastoma," said Steven A.